Comorbidity and survival in lung cancer patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 7, 2015, Pages 1079-1085

  Islam, K M Monirul ^a   Jiang, Xiaqing ^a   Anggondowati, Trisari ^a   Lin, Ge ^b,c   Ganti, Apar Kishor ^a,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEVADA   (United States)

^c Nebraska Department of Health and Human Services Joint Public Health Data Center   (United States)

^d VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHILD; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; DEMENTIA; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HOSPITAL DISCHARGE; HUMAN; INFANT; KIDNEY DISEASE; LIVER DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; OVERALL SURVIVAL; PRIORITY JOURNAL; UNITED STATES; HEART FAILURE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEBRASKA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; SURVIVAL RATE; YOUNG ADULT;

EID: 84941774745     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0036     Document Type: Article

References (29)

1. ACS. Cancer facts and figures 2014. American Cancer Society: American Cancer Society; 2014.
2. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44.
3. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study. Lung Cancer 1998; 21:105-13.
4. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer 2003;103:792-802.
5. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441-7.
6. Deleuran T, Thomsen RW, Norgaard M, Jacobsen JB, Rasmussen TR, Sogaard M. Comorbidity and survival of Danish lung cancer patients from 2000-2011: A population-based cohort study. Clin Epidemiol 2013;5:31-8.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
8. Hsu CL, Chen JH, Chen KY, Shih JY, Yang JC, Yu CJ, et al. Advanced nonsmall cell lung cancer in the elderly: The impact of age and comorbidities on treatmentmodalities and patient prognosis. JGeriatr Oncol 2015;6:38-45.
9. Ganti AK, Siedlik E, Marr AS, Loberiza FR Jr, Kessinger A. Predictive ability of Charlson comorbidity index on outcomes from lung cancer. Am J Clin Oncol 2011;34:593-6.
10. Iachina M, Green A, Jakobsen E. The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: A combination of survival, staging and resection models with missing measurements in covariates. BMJ Open 2014;4:e003846.
11. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: A review. Clin Epidemiol 2013;5:3-29.
12. Rueth NM, Parsons HM, Habermann EB, Groth SS, Virnig BA, Tuttle TM, et al. Surgical treatment of lung cancer: predicting postoperative morbidity in the elderly population. J Thorac Cardiovasc Surg 2012;143: 1314-23.
13. Lin G, Ma J, Zhang L, Qu M. Linking cancer registry and hospital discharge data for treatment surveillance. Health Informatics J 2013;19:127-36.
14. Young Jr J, Roffers S, Ries L, Fritz A, Hurlbut A. SEER Summary Staging Manual-2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; NIH Pub. 2001.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613-9.
16. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120: 1290-314.
17. Inal A, Kaplan MA, Kucukoner M, Urakc Z, Iskdogan A. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer? Rev Port Pneumol 2014;20:62-8.
18. Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: A review. J Clin Epidemiol 2001;54:661-74.
19. Janssen-Heijnen M, Lemmens VEPP, van den Borne B, Biesma B, Oei S, Coebergh J. Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: A population-based study in the Netherlands. Crit Rev Oncol Hematol 2007;62:172-8.
20. Battafarano RJ, Piccirillo JF, Meyers BF, Hsu H-S, Guthrie TJ, Cooper JD, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;123:280-7.
21. Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004; 22:3099-103.
22. Patel P, Henry LL, Ganti AK, Potti A. Clinical course of lung cancer in patients with chronic kidney disease. Lung Cancer 2004;43:297-300.
23. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53:93-106.
24. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999;91:22-36.
25. Dalton SO, Frederiksen B, Jacobsen E, Steding-Jessen M, -sterlind K, Schuz J, et al. Socioeconomic position, stage of lung cancer and time between referral and diagnosis in Denmark, 2001-2008. Br J Cancer 2011;105: 1042-8.
26. Pagano E, Filippini C, Di Cuonzo D, Ruffini E, Zanetti R, Rosso S, et al. Factors affecting pattern of care and survival in a population-based cohort of non-small-cell lung cancer incident cases. Cancer Epidemiol 2010;34: 483-9.
27. Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol 2012;30:1447-55.
28. Luchtenborg M, Jakobsen E, Krasnik M, Linklater KM, Mellemgaard A, Møller H. The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. Eur J Cancer 2012;48: 3386-95.
29. Dy SM, Sharkey P, Herbert R, Haddad K, Wu AW. Comorbid illnesses and health care utilization among Medicare beneficiaries with lung cancer. Crit Rev Oncol Hematol 2006;59:218-25.